Arcutis Seeks FDA Nod for ZORYVE in Infants as Young as 3 Months
Event summary
- Arcutis submitted an sNDA to expand ZORYVE’s indication to infants aged 3 months to <24 months with mild-to-moderate atopic dermatitis.
- Submission supported by Phase 1 and Phase 2 trial data showing safety, tolerability, and efficacy in 101 infants.
- ZORYVE is already approved for atopic dermatitis in children aged 2–5 years; expansion would address a critical unmet need.
- Atopic dermatitis affects ~1 million U.S. children under age 2, with limited non-steroidal treatment options available.
The big picture
Arcutis’ sNDA submission reflects a strategic push to dominate the pediatric dermatology space by addressing a critical gap: safe, effective treatments for infants. With only one other FDA-approved non-steroidal option available, approval could position ZORYVE as a cornerstone therapy, reinforcing Arcutis’ leadership in immuno-dermatology.
What we're watching
- Regulatory Timing
- The pace at which the FDA reviews Arcutis’ sNDA will determine when ZORYVE could enter this underserved market.
- Market Positioning
- Whether Arcutis can leverage this expansion to solidify ZORYVE as a foundational therapy across all pediatric age groups.
- Competitive Dynamics
- How this move affects rivals targeting the same atopic dermatitis patient population, particularly in non-steroidal treatments.